Chongqing Genrix Biopharmaceutical Co. Ltd. A (688443.SS) stock: key figures, P/E, revenue and dividend
Health Care · China · ISIN CNE100006KG8
Chongqing Genrix Biopharmaceutical Co. Ltd. A financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 30.09 m CNY | 230.73 m CNY |
| Gross profit | 24.79 m CNY | 214.63 m CNY |
| Operating income | -835.91 m CNY | -545.56 m CNY |
| EBIT | -768.38 m CNY | -504.24 m CNY |
| Net income | -797.27 m CNY | -535.65 m CNY |
| Diluted EPS – continuing operations | -2.17 CNY | -1.46 CNY |
Full history since 2021, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Chongqing Genrix Biopharmaceutical Co. Ltd. A
Chongqing Genrix Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, production, and sale of antibody drugs in China. It develops GR1501, a monoclonal antibody for the treatment of axial spondyloarthritis; GR1801, an anti-rabies virus G protein bispecific antibody; GR1802, an anti-IL-4Ra monoclonal antibody; GR1603, a monoclonal antibody for systemic lupus erythematosus; GR2002 an anti-TSLP bispecific antibody; WM1R3, a family receptor bispecific antibody; GR2001, a monoclonal antibody; GR2201, a monoclonal antibody for VZV infection; GR2302, a recombinant CD3xpMHC (HBV-S); GR2301, a recombinant anti-IL-15 monoclonal antibody; GR2304, a recombinant CD3xpMHC (PRAME); GR2502, a TCR-based antibody (TCRm); GR2603, a recombinant humanized trispecific antibody; GR1803, a bispecific antibody for multiple myeloma; GR1901, a bispecific antibody; WM202 a bispecific antibody; WM215, a single-domain antibody; GR1401, an anti-EGFR monoclonal antibody; and GR1405 an anti-PD-L1 monoclonal antibody. The company was founded in 2015 and is based in Chongqing, China.
More stocks
- Interroll Holding AG (INRN.SW)
- Denka Co Ltd (4061.T)
- Qfin Holdings Inc (QFIN)
- Xiamen Voke Mold & Plastic Engineering Co. Ltd. (301196.SZ)
- Zhejiang Wanma Co Ltd (002276.SZ)
- Triumph Financial, Inc. (TFIN)
- Microport Scientific Corp (853.HK)
- Ellington Financial Inc. (EFC)
- Beijing Balance Medical Technology Co Ltd (688198.SS)
- Wuxi Shangji Automation Co Ltd (603185.SS)
- Green Thumb Industries Inc. (GTBIF)
- Greatech Technology Bhd (0208.KL)
Not investment advice. All data without warranty, price as of 03.11.2026. Details in the risk notice.